Glenmark Pharma Latest News

  1. Glenmark gains on getting tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets

    The Horizant market achieved annual sales of approximately $99.5 million
    Date:31-12-2020

  2. Glenmark gets tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets

    The Horizant market achieved annual sales of approximately $99.5 million
    Date:31-12-2020

  3. Glenmark Pharmaceuticals gets USFDA’s nod for Tadalafil Tablets

    The Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market achieved annual sales of approximately $125.5 million
    Date:31-12-2020

  4. Glenmark inches up on launching Remogliflozin + Vildagliptin fixed dose combination

    The fixed drug combination is indicated for the management of Type 2 diabetes
    Date:29-12-2020

  5. Glenmark becomes first company to launch Remogliflozin + Vildagliptin fixed dose combination

    The fixed drug combination is indicated for the management of Type 2 diabetes
    Date:29-12-2020

  6. Glenmark Pharmaceuticals informs about media release

    Glenmark Pharmaceuticals has informed that the company has attached media release on 23rd December 2020, titled ‘Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializi...

    Date:23-12-2020

  7. Glenmark Pharmaceuticals shines as its arm enters into licensing agreement with Menarini Group

    Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these markets
    Date:23-12-2020

  8. Glenmark Pharmaceuticals’ arm enters into licensing agreement with Menarini Group

    Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these markets
    Date:23-12-2020

  9. Glenmark Pharmaceuticals moves up on getting tentative approval for Dabigatran Etexilate Capsules

    The 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million
    Date:21-12-2020

  10. Glenmark Pharmaceuticals gets tentative approval for Dabigatran Etexilate Capsules

    The 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million
    Date:21-12-2020
Related Glenmark Pharma Links: Glenmark Pharma Analysis, Glenmark Pharma Reports,
Glenmark Pharma Share Price, Healthcare News
Return to Top
Puchho Befikar